Nektar Therapeutics NKTR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's EPS (diluted)?
- Nektar Therapeutics (NKTR) reported EPS (diluted) of -$1.82 in Q1 2026.
- How has Nektar Therapeutics's EPS (diluted) changed year-over-year?
- Nektar Therapeutics's EPS (diluted) increased by 49.7% year-over-year, from -$3.62 to -$1.82.
- What is the long-term trend for Nektar Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Nektar Therapeutics's EPS (diluted) has grown at a -66.5% compound annual growth rate (CAGR), from -$792.07 to -$10.03.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.